Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.

American journal of therapeutics - 1 Jan 2000

Cao Susu, Tao Qianshan, Wang Jia, Zhang Qing, Dong Yi

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antimetabolites, Antineoplastic
Share to Carrier Proteins
Share to Decitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nuclear Proteins

Share to Receptors, Colony-Stimulating Factor

Share to Repressor Proteins

Share to Treatment Outcome

Source

Identifiers

PMID: 39292831
DOI: 10.1097/MJT.0000000000001411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Response of Chronic Neutrophilic Leukemia With CSF3R T618I, SETBP1, and ASXL1 Mutations After Decitabine Therapy.PMID 39292831Read ↗

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsSemantic proximity Read ↗

Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.Semantic proximity Read ↗

Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.Semantic proximity Read ↗

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.Semantic proximity Read ↗

Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinibSemantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

Genomics of chronic neutrophilic leukemia.Semantic proximity Read ↗

Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.Semantic proximity Read ↗

What's different about atypical CML and chronic neutrophilic leukemia?Semantic proximity Read ↗

Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.Semantic proximity Read ↗

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.Semantic proximity Read ↗

CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.